ArticleEJHaem2026
Persistence to Multiple Myeloma Treatments Given at First Relapse-Results From the Australian Real-World OPTIMISE Study.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Daratumumab became publicly available in Australia in 2021 in combination with bortezomib and dexamethasone (DVd), as a second-line (2L) therapy for multiple myeloma (MM). We evaluated real-world persistence to any MM treatment after first relapse before and after DVd availability using the Pharmaceutical Benefits Scheme 10% sample dataset. Methods: Dispensing records for adults receiving 2L MM treatment from January 2018 to December 2020 (Period 1) and January 2021 to April 2025 (Period 2) were analyzed using Kaplan-Meier to determine treatment persistence. Results: Eighty patients were included in Period 1 and 290 in Period 2. Median treatment persistence was longer in Period 2 (15 months) than Period 1 (9.8 months) (hazard ratios [HRs]: 0.46; 99.9% CI: 0.23-0.90; Conclusions: The observed improvements in treatment persistence among patients with MM including those refractory to lenalidomide, following reimbursement-driven availability of DVd, indicate meaningful clinical benefit in routine practice after the introduction of novel therapies, and underscores the need for sustained access to diverse and effective treatment options for relapsed MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.